Access to Medicines | Intellepedia

In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies

The article examines India’s policy on compulsory licensing for COVID-related medical technologies, echoing Prof. Arul Scaria’s critique of current government inaction. It highlights the legal and historical basis for compulsory licensing and argues for its strategic use to ensure public access to vaccines and medicines.

Intellectual Property, Accessibility and Public health

This analysis explores the relationship between intellectual property, accessibility, and public health, with a focus on recent global developments amid COVID-19. It highlights key policy measures, compulsory licensing, and collaborative efforts to promote access to medical technologies.

Generication of Public Interest

This article explores how public interest has guided Indian patent law, often supporting generic drug companies over innovators. It argues for a balanced approach to public interest that considers both affordability and pharmaceutical innovation.

IPR and Access to Affordable Medicines: How affordable are We?

This post examines the complex interaction between intellectual property rights and access to affordable medicines in India. It provides a legal analysis of policy challenges and judicial decisions, highlighting the ongoing balance between innovation and public access to healthcare.

‘Affordability, Availability, Accessibility of medicines’

The post examines key outcomes from a national conference on access to medicines in India, with a focus on pharmaceutical pricing, IPR, and related policy challenges. It analyses expert perspectives on affordable medicine, patent law, and healthcare systems in an Indian context.

Roche loses again

The Indian Patent Office has revoked Roche’s Valganciclovir patent, emphasizing Section 3d and public interest. This decision strengthens access to medicines in India and curbs evergreening by pharmaceutical companies.